Introduction
Patients with intermediate and poor-risk acute myeloid leukemia (AML) who achieve complete remission after induction chemotherapy benefit from allogeneic hematopoietic cell transplantation (HCT) (2) . The success of HCT is due, at least in part, to T cells and natural killer (NK) cells exerting a graft versus leukemia (GVL) effect capable of eradicating remaining AML cells. We have shown that haploidentical NK cell infusions can be used safely to improve outcomes in patients with refractory AML in a non-transplantation setting (3, 4) . However, unlike T-cells, which generate antigen-specific receptors to drive their effector functions, NK cells rely on surface receptors to bind a potential target cell. Interactions between NK cell activating and inhibitory receptors with target cell ligands determine whether or not an NK cell will elicit an immune response. According to the missing-self hypothesis, the lack of expression of inhibitory ligands (usually MHC class I molecules) and the overexpression of activating ligands by target cells determines whether NK cell killing occurs (5, 6) . Thus, the ability of NK cells to mount an immune response against AML target cells is largely dependent on the target surface expression of ligands. This limitation is a major obstacle to NK cell therapy as responses may lack potency and specificity for leukemic targets.
In a normal physiologic setting, antibody binding triggers antibody-dependent cell cytotoxicity (ADCC), a process involving NK cell activation, the release of cytokines and cytolytic granules, and induction of target cell apoptosis. ADCC is primarily mediated by the low affinity Fc receptor CD16 (FcγRIIIA or CD16A). CD16 is a potent NK cell activating receptor that, upon signaling, induces phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs), triggering the release of lytic granules and cytokines such as interferon (IFN-γ) and tumor necrosis factor (TNF-α) (7) (8) (9) . In addition, CD16 downregulation in NK cells occurs when these cells interact with target cells (10) , an effect that we demonstrated to be a result of ectodomain shedding of CD16 upon NK cell activation. CD16 shedding by NK cells is mediated by the trans-membrane glycoprotein, a disintegrin and metalloprotease-17 or ADAM17 (11) . These data show the central importance of CD16 in triggering NK cell-mediated ADCC.
One approach to improving NK cell therapy may be the use of antibodies that are designed to specifically bind to both target antigens and NK cell activating receptors.
We have recently demonstrated that CD16-directed bi-specific (CD16x19) and trispecific (CD16x19x22) single chain fragment variable (bscFv and tscFv) recombinant agents directly trigger NK cell activation through CD16, significantly increasing NK cell cytolytic activity and cytokine production against lymphoid tumor targets (12, 13) . In the present study, we designed a novel bi-specific killer cell engager antibody (BiKE), developed specifically to signal through CD16 and target the myeloid differentiation antigen CD33 (named CD16x33 BiKE). CD33 is a myeloid surface antigen expressed on the AML blasts of approximately 85% of patients (14) . We tested whether CD16x33 BiKE enhances NK cell activation against CD33 + AML cells using the HL60 cell line and primary AML cells. In addition, we examined whether ADAM17 inhibition, preventing CD16 shedding, enhances the effector function of NK cells against leukemia targets when combined with CD16x33 BiKE.
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Flow Cytometry
Single-cell suspensions were stained with the following monoclonal antibodies (mAb): PE/Cy7-conjugated CD56 (HCD56; BioLegend), ECD-conjugated CD3 (UCHT1; Beckman Coulter), FITC-conjugated CD14 (M5E2; BioLegend), APC/Cy7-conjugated CD16 (3G8; BioLegend), FITC-conjugated CD33 (P67.6; BD Biosciences), PerCP/Cy5.5-conjugated anti-human CD107a (LAMP-1) (H4A3; BioLegend), Pacific Blue-conjugated anti-human IFN-γ (4S.B3; BioLegend), Alexa Fluor647-conjugated anti-human TNF-α (Mab11; Biolegend), PE anti-human CD158a/h (KIR2DL1/S1) (HPMA4; Biolegend), PE anti-human CD158b (KIR2DL2/L3, NKAT2) (DX27; Biolegend), and PE anti-human CD158e1 (KIR3DL1, NKB1) (DX9; Biolegend). HLA expression was analyzed using FITC-conjugated antihuman HLA ABC (MCA81F, AbD Serotec). Flow cytometry assays were performed on a LSRII 11-color flow cytometer (BD Biosciences), and all data were analyzed with FlowJo 9.3.2 software (TreeStar).
Construction, expression, and purification of bscFv CD16 x CD33 (CD16x33) BiKE
Synthesis and assembly of hybrid genes encoding the CD16x33 BiKE reagent were accomplished by using DNA shuffling and DNA ligation techniques as previously described (15) . The fully assembled gene (from 5' end to 3' end) consisted of an NcoI restriction site, an ATG initiation codon, the VH and VL regions of anti-human control of an isopropyl-β-D-thiogalactopyranoside (IPTG) inducible T7 promoter.
DNA sequencing analysis (Biomedical Genomics Center, University of Minnesota) was used to verify that the gene sequence was correct and had been cloned in frame.
Bacterial protein expression and purification by ion exchange and size exclusion chromatography were performed as previously described (15) .
ADAM17 inhibition and MHC-class I antibody-blocking experiments
A highly selective ADAM17 inhibitor (INCB003619) from Incyte (Wilmington, DE) was added at a concentration of 2 μM to purified NK cells 30 minutes before testing.
Mouse mAb IgG1 clone HP-1F7 (kindly provided by M. Lopez Botet) was used as a positive control for pan-HLA blocking. The mAb HP-1F7 effectively binds to the alpha chain of HLA-A, -B, -C, -E and -G, and blocks all NK cell inhibitory receptor engagement (17) (18) (19) . Target cells were preincubated for 30 minutes with anti-HLA mAb to a final concentration of 20 ug/mL.
Cytokine/Chemokine Production and CD107a Degranulation Assay
Purified NK cells and PBMCs were incubated overnight at 37ºC, 5% CO2 in basal medium (RPMI supplemented with 10% fetal calf serum and 1% penicillin/streptomycin). Cells were washed and treated with 5 ug/mL of bscFv CD16x33 BiKE (or as described in figures) and incubated for an extra 30 mins. Antihuman CD107a mAb was added alone or with target cells (HL60, Raji, de novo primary AML, or relapse/refractory AML; E:T ratios 2:1 or as described in figures) and incubated for 1 hour. GolgiStop (1:1500) and GolgiPlug (1:1000; both from BD Biosciences) were added to cell cultures, which were incubated for an additional 4
Research. hours. Cells were then harvested and stained with mAb CD56, CD3, CD16, and KIR (CD158a, CD158b and NKB1) before fixation and permeabilization. Permeabilized cells were stained for intracellular TNF-α and IFN-γ with an anti-human TNF-α antibody and an anti-human IFN-γ antibody, respectively. CD3, CD56, CD16, KIR, CD107a, TNF-α, and IFN-γ expression was evaluated by FACS analysis.
Chromium Release Cytotoxicity Assay
Direct cytotoxicity assays were performed by standard 4-hour 51 Cr-release assays using NK cells pre-treated with bscFv CD16x33 BiKE and HL60 or Raji targets as indicated. 51 Cr released by specific target cell lysis was measured by a gamma scintillation counter, and the percent target cell lysis was calculated as follows:
[(experimental lysis -spontaneous lysis)/(maximal lysis -spontaneous lysis)] x 100.
Statistical Analysis
Data were summarized with mean and standard error (mean ± SEM). For comparisons between independent samples, Student's T-test was used. For comparisons of matched samples, paired T-test was used. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results

CD16x33
BiKE specificity enhances NK cell effector functions against CD33 +
HL60 AML cells
We first determined whether the CD16x33 BiKE induces NK cell effector function against the HL60 cell line (CD33 + ). CD16x33 BiKE at the indicated concentrations induced NK cells to release lytic granules (CD107a) and produce cytokines (TNF-α and IFN-γ) (Fig. 1A) . In addition, CD16x33 BiKE induced target cell death as measured by chromium release assay (Fig. 1B) . Moreover, a dose-dependent increase in NK cell function was observed in response to CD16x33 BiKE, with a plateau at 5 ug/mL and above. On the basis of these initial results, we selected a dose of 5 ug/mL of the CD16x33 BiKE for future experiments.
For NK cells to be effective therapeutically, they must function at low effector:target (E:T) ratios. CD16x33 BiKE at 5 ug/mL enhanced NK cell degranulation (CD107a expression) and TNF-α and IFN-γ production, independently of the E:T target ratio (Fig. 1C) . Using a standard chromium release assay and HL60 targets, we observed enhanced killing with the CD16x33 BiKE at all E:T ratios, with diminished absolute killing at lower E:T ratios as expected (Fig. 1D) . Further, CD16x33 BiKE-mediated killing was specific as this antibody only potentiated NK cell functional activity against CD33 + HL60 cells but not CD33 -RAJI cells (Fig. 1E ).
In addition to NK cells, the Fc receptor CD16A is expressed on the surface of monocytes and macrophages (20) . To determine whether CD16A + cells other than NK cells could contribute to the observed CD16x33 BiKE-mediated cytotoxicity, we performed a 4-hour chromium release assay with or without CD16x33 BiKE added to PBMC-containing NK cells or monocytes ( Fig. 2A ). CD16x33 BiKE mediated cytotoxicity was specific for NK cells, suggesting that this reagent activates CD16 + NK cells to directly lyse CD33 + targets but not CD16A + monocytes.
In addition to CD33 expression on AML cells, CD33 expression on other myeloid differentiated cells, such as monocytes (14, 21) , has the potential to interfere with target cell killing. We tested whether autologous CD33 + monocytes interfere with the ability of CD16x33 BiKE to induce NK cell cytotoxicity and cytokine release.
Flow cytometry based function indicated that CD16x33 BiKE induced lower level degranulation and cytokine release against autologous CD33 + monocytes but more robust NK cell function was induced by HL60 targets (Fig. 2B) . Furthermore, when PBMCs (containing NK cell and CD33 + monocytes) were treated with CD16x33 BiKE, we observed enhanced CD107a degranulation and INF-γ secretion against HL60 targets than when NK cells were cultured with CD33 + monocytes alone under similar conditions. These results suggest that the presence of CD33 + monocytes does not inhibit HL60 target activation of NK cells and that NK cells could be targeting both the HL60 and the monocyte population leading to enhance NK cell activation.
Despite this potential target competition, cytotoxicity from PBMCs (containing NK cells and monocytes) against HL60 targets is significantly enhanced by CD16x33
BiKE treatment (Fig 2A) . Lastly, CD33 + unlabeled HL60 targets were admixed with chromium labeled CD33 -Raji targets and no killing occurred (data not shown). This leads to the conclusion that CD16x33 BiKE does not activate NK cells sufficient to mediate a bystander effect against CD33 -targets. (Fig. 2C) . In contrast, CD16 expression was markedly downregulated after treatment with the CD16x33 BiKE, an effect which was greater when NK cells were also cultured with HL60 targets than when NK cells were cultured with autologous CD33 + monocytes. Our data demonstrate a direct correlation between NK cell activation and loss of CD16 expression after exposure to the CD16x33 BiKE.
CD16x33 BiKE induces NK cell activation against de novo CD33 + AML cells, an effect enhanced by ADAM17 inhibition
To explore whether NK cell function against CD33 + AML blasts is enhanced by treatment with the CD16x33 BiKE, we purified NK cells from healthy donors and cultured them for 4 hours with or without CD33 + AML blasts obtained from a patient with de novo AML. NK cells alone had no cytotoxic or cytokine release activity against de novo AML targets (Fig. 3A) . In contrast, the addition of CD16x33
BiKE to the cell culture resulted in significant NK cell cytolytic activity and cytokine release against CD33 + AML blasts (Fig 3A and 3B) .
We next explored whether inhibition of ADAM17 (with the purpose of preventing (Fig 4) . Together, these results suggest that the CD16x33 BiKE has the ability to overcome inhibitory signals, which under physiologic conditions inhibit AML recognition by NK cells.
CD16x33 BiKE and ADAM17 inhibition leads to potent NK cell activity against refractory CD33 + AML cells
Immune sensitivity against de novo AML and refractory disease may differ. We obtained 10 bone marrow samples from patients with refractory AML; 8 of 10 samples expressed CD33 (Fig. 5A ). CD16x33 BiKE substantially activated NK cells against these CD33 + refractory AML targets (Fig 5B) . Combination treatment with CD16x33 BiKE plus the ADAM17 inhibitor resulted in enhanced NK cell activation, especially cytokine production. In contrast, no significant NK cell activation was observed with the CD16x33 BiKE against the AML samples that lacked CD33 expression (CD33 -AML) targets (Fig 5C) . Our results show that not only does CD33
Research. patients with CMV reactivation in the first 100 days after transplant).
NK cell CD16 expression, measured by flow cytometry, was performed on these samples and compared to NK cell CD16 expression from healthy donors (Fig. 6A ).
Our results demonstrate that CD16 reconstitution occurs in a time-dependent manner, with higher CD16 expression observed at 1 year than at 3 months post-UCBT. In addition, no differences in CD16 expression were observed between CMV reactivating patients and those without reactivation. This is not a surprise since monocytes can express NK activating ligands such as CD48, the ligand for the activating receptor 2B4 (26) . To minimize this potential "monocyte sink", treating AML patients with chemotherapy to minimize CD33 target competition may be warranted but this needs to be balanced with the chemotherapy effect on the NK cells.
It has been previously recognized that HLA class I expression, a strong inhibitory ligand, is preserved on acute myeloid leukemia blasts at diagnosis and at relapse (22, 27) . 
mobilization (12).
We investigated how the effector function of a therapeutic antibody signaling through CD16, can be enhanced by inhibition of ADAM17. The ADAM family of multidomain proteins is involved in both proteolysis and cell adhesion (13) . These molecules play a major role in processing or shedding of cell membrane proteins, thereby altering the phenotype (and likely function) of cells. ADAM17 is responsible for shedding of CD16 after NK cell activation (11) , but has also been recognized as a potential target for cancer therapy because it is widely overexpressed by many tumors (1, 28, 29) . ADAM17 has been reported to have a direct functional role in controlling proliferation and migration of tumors cells and is an important protein involved in controlling endothelial cell migration in angiogenesis (30) (31) (32) . Our studies show a new immune-mediated mechanism of anti-tumor activity by ADAM17 inhibition. We found that ADAM17 inhibition and NK cell activation with CD16x33 BiKE resulted in increased cytotoxicity and cytokine secretion of IFN-γ and TNF-α, a combination optimal for therapeutic use. We acknowledge that our results are limited to in vitro evaluation and development of in vivo models are planned to substantiate the combined treatment with CD16x33 BiKE and ADAM17 inhibition in tumor bearing animals. Since ADAM17 was originally recognized for being the major protein responsible for the cleavage of the trans-membrane proteins TNF-α (33), inhibitors of ADAM17 have been used in animal models and have showed to be effective in models of septic shock and rheumatoid arthritis (34, 35 
We have recently described that CD62L (L-selectin), the cell adhesion molecule expressed by most leukocytes (including NK cells), is also shed by ADAM17 (11) Relapse mortality following allogeneic HCT remains a major challenge in the care of patients with AML (36) and is likely to increase now that reduced-intensity regimens are used in older patients who tend to have more aggressive disease (37).
Thus, development of new therapeutic strategies to improve GVL posttransplantation is urgently needed. After allogeneic HCT, NK cells mediate GVL by the production of inflammatory cytokines and by direct target lysis. We have previously demonstrated that target cell-induced IFN-γ production is markedly diminished in recipients of allogeneic transplantation (38) . The current study explores the potential effect of using a CD16x33 BiKE to induce GVL after UCBT. 
